A gout drug has been approved by the FDA, the first in 40 years, with three more in the wings. What accounts for this sudden slew of gout therapies? Jill U. Adams investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 July 2009
In the version of this article initially published, the incidence of gout was incorrectly stated to be in the hundreds of millions worldwide and 300 million in the US (page 309, paragraph 2). The incidence is known for industrialized countries, not worldwide. In the US, the number is 3 million. The last five lines of the paragraph should have read, “including about 1 in 100 adult men in industrialized countries (an estimated 3 million in the US according to the Centers for Disease Control).” The errors have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Adams, J. New relief for gout. Nat Biotechnol 27, 309–311 (2009). https://doi.org/10.1038/nbt0409-309
Issue Date:
DOI: https://doi.org/10.1038/nbt0409-309
This article is cited by
-
A study about excellent xanthine oxidase inhibitory effects of new pyridine salts
Monatshefte für Chemie - Chemical Monthly (2021)
-
Erratum: New relief for gout
Nature Biotechnology (2009)
